Relationship between the long-term effects of intraperitoneal chemotherapy and the expression of p53 and p21 in patients with gastric carcinoma at stage IIIa and stage IIIb

International Surgery

Volumn 82, Issue 2, 1997, Pages 170-174

  Ikeguchi, M ^a   Saito, H ^a   Katano, K ^a   Gomyo, Y ^a   Tsujitani, Sh ^a   Maeta, M ^a   Kaibara, N ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Advanced gastric cancer; Continuous hyperthermic peritoneal perfusion; p21; p53

Indexed keywords

ANTINEOPLASTIC AGENT; MITOMYCIN C; PROTEIN P21; PROTEIN P53; UFT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PROTEIN EXPRESSION; STOMACH CARCINOMA; STOMACH SURGERY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; ONCOGENE PROTEIN P21(RAS); RANDOM ALLOCATION; STATISTICS, NONPARAMETRIC; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030861199     PISSN: 00208868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Iwanaga T, Koyama H, Furukawa H, Taniguchi H, Wada A, Tateishi R. Mechanism of late recurrence after radical surgery for gastric cancer. Am J Surg 1978;135:637-640.
2. Kaibara N, Iitsuka Y, Kimura A, Kobayashi Y, Hirooka Y, Nishidoi H et al. Relationship between area of serosal invasion and prognosis in patients with gastric cancer. Cancer 1986;60:136-139.
3. Koga S, Kaibara N, Iitsuka Y, Kudo H, Kimura A, Hiraoka H. Prognostic significance of intraperitoneal free cancer cells in gastric cancer patients. J Cancer Res Clin Oncol 1984;108:236-238.
4. Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 1994;73:2048-2052.
5. Ikeguchi M, Kondou A, Oka A, Tsujitani S, Maeta M, Kaibara N. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg 1995; 161:581-586.
6. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990;87:9958-61.
7. Yamaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonemura Y, Miwa K et al. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 1992;70:2778-84.
8. Lundin J, Nordling S, von Boguslawsky K, Robert PJ, Haglund C. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology 1996;53:104-111.
9. Low SW, Jacks T, Housman DE, Ruley HE. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci USA 1994;91:2026-2030.
10. Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996;2:811-814.
11. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for p53-mediated G1 arrest in human cancer cells. Cancer Res 1995;55: 5187-5190.
12. Japanese Research Society for Gastric Cancer. The General Rules for the Gastric Cancer Study. First English Edition, Tokyo, 1995.
13. Hsu SM, Raine L, Fanger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580.
14. Kawai K, Serizawa A, Hamana T, Tsutsumi Y. Heat-induced antigen retrieval of proliferating cell nuclear antigen and p53 protein in formalin-fixed, paraffin-embedded sections. Pathol Int 1994;44:759-764.
15. Finaly CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-539.
16. Shiohara M, EL-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R et al. Absence of WAF1 mutation in a variety of human malignancies. Blood 1994;84:3781-3784.
17. ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Oncogene 1995;11:1487-1498.
18. Cipl. Oncogene 1995;11:1675-1683.
19. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-3395.